Peptide fact checks.

LEADER tested a defined cardiovascular composite in a high-risk type 2 diabetes population, not lifespan extension in the general population.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Adults with type 2 diabetes and high cardiovascular risk in LEADER.

The phase 2 trial reported dose-dependent weight reduction over 48 weeks in a defined adult population.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Adults meeting the phase 2 obesity-trial criteria over 48 weeks.

It remains investigational. FDA says retatrutide is not a component of an approved drug and has not been found safe and effective for any condition. Positive trial results and sponsor announcements are not marketing approval.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

United States regulatory status as reviewed August 1, 2026.

Lilly reported average weight reduction of up to 20.8% in TRIUMPH-2 and up to 22.6% in TRIUMPH-3 at 80 weeks. These are sponsor-reported topline efficacy-estimand figures and group averages, not individual outcomes, and no full peer-reviewed report of either trial was available in the records reviewed here.

What this answer is based on

Study results reported by its sponsor
This answer uses a trial result reported by the study sponsor. A full report checked by other experts may not be available yet.

Applies to

Adults meeting the TRIUMPH-2 (obesity or overweight with type 2 diabetes) and TRIUMPH-3 (severe obesity with established cardiovascular disease) entry criteria at 80 weeks, as disclosed by Lilly in July 2026.

TRIUMPH-3 was not a definitive cardiovascular-outcomes trial. The sponsor reported a hazard ratio of 0.82 (95% CI 0.55 to 1.22) for the five-component major adverse cardiovascular event measure and 1.12 (95% CI 0.64 to 1.96) for the three-component measure. Both intervals include 1.0 and are wide, so studying a molecule in people with cardiovascular disease is not the same as showing it prevents events.

What this answer is based on

Study results reported by its sponsor
This answer uses a trial result reported by the study sponsor. A full report checked by other experts may not be available yet.

Applies to

The TRIUMPH-3 cardiovascular-event analyses as disclosed by Lilly in July 2026, pending a full report.

Lilly states it plans to submit retatrutide for obesity in the first quarter of 2027. A planned submission is a future corporate action, not regulatory acceptance, approval, a prescribing label, or a launch date. Until an approval is recorded by the regulator, the accurate U.S. status remains investigational.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The sponsor-stated first-quarter 2027 U.S. submission plan as reviewed August 1, 2026.

A matching label name does not establish sequence, purity, sterility, formulation, storage, or clinical equivalence. FDA warns that retatrutide products sold directly to consumers as research material are unapproved and of unknown quality.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Products outside an authorized clinical-development supply chain.

A phase 2 study examined cagrilintide alone. A later large study had separate cagrilintide-alone and CagriSema groups. The results apply only to each defined study group.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Adults without diabetes. The 26-week study required BMI 30 or higher, or BMI 27 or higher with high blood pressure or unhealthy blood-fat levels. The 68-week study required BMI 30 or higher, or BMI 27 or higher with a weight-related health problem. All groups received food and activity guidance. Each result applies only to its study group and period. The CagriSema result does not establish the same result for cagrilintide alone.

FDA's current page says cagrilintide is not a component of an approved drug and has not been found safe and effective for any condition. Human research does not equal FDA approval.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

United States regulatory status as reviewed August 30, 2026.

CagriSema is the investigational combination of cagrilintide and semaglutide. Evidence from the combination is not evidence for cagrilintide alone.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

The separate cagrilintide-alone phase 2 and later CagriSema study reviewed here.

FDA's current unapproved-GLP-1 page says cagrilintide cannot be used in compounding under federal law. This is a United States status statement, not a finding that every online product is identical or safe.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

United States compounding status as reviewed August 30, 2026.

FDA's substance record lists SS-31 and elamipretide as synonyms. It also lists development names such as MTP-131 and Bendavia. A name match does not prove that an online vial has the same quality or product controls.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

FDA substance identity mapping; not a quality or product-equivalence finding.

FDA granted accelerated approval for Forzinity to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. Accelerated approval uses an intermediate measure and requires a confirmatory study.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The Forzinity label and FDA approval records as reviewed August 30, 2026.

FDA says the randomized study did not show superiority to placebo on its initial walking and fatigue measures. The approval used a knee-extensor muscle-strength measure and later extension data.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

The randomized Barth syndrome study and its defined measures; this does not establish a result for other diseases or products.

The 24-week MMPOWER-3 trial did not meet its main goals for six-minute walk distance or fatigue compared with placebo.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

The 218 adults with genetically confirmed primary mitochondrial myopathy studied in MMPOWER-3 for 24 weeks.

A small healthy-aging study measured a laboratory energy measure. It did not establish better daily energy, less fatigue, longer life, or slower aging.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Healthy older adults in the single study reviewed; a laboratory measure is not the same as a long-term health outcome.

Forzinity is a specific FDA-approved product. An ingredient name or research vial does not establish the same formulation, manufacturing controls, strength, sterility, or clinical evidence.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The named Forzinity product compared with any other material sold under the SS-31 or elamipretide name.

Yes. CASTA and other randomized studies tested the named product in defined groups and settings. The existence of these studies does not prove a benefit for every outcome or product.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

The exact Cerebrolysin product, study group, comparison, outcome, and follow-up period in each randomized trial.

CASTA enrolled 1,070 adults, but its main combined recovery measure showed no significant difference between Cerebrolysin and placebo. A subgroup finding was not the main planned result and does not prove a general recovery benefit.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

CASTA: adults with acute ischemic stroke studied for up to 90 days. The result applies to its planned primary measure and study population.

No FDA-approved U.S. Cerebrolysin product was identified in the reviewed approval database. An FDA substance record or orphan designation does not mean that FDA approved a product.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

United States regulatory status as reviewed August 30, 2026. Austrian authorization is a separate country status.